Moreover, targeting the inflammasome could also be beneficial to offset some of the side effects of glucocorticoids such as obesity and glucose intolerance, as NLRP3 overactivation plays a role in these metabolic disorders [16]. This evidence concerns the gene NLRP3 and obesity due to melanocortin 4 receptor deficiency.